Minerva Neurosciences, Inc.

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Large Molecule

Other Names/Subsidiaries

  • Cyrenaic Pharmaceuticals, Inc.
  • Mind-NRG SA
  • Sonkei Pharmaceuticals, Inc.
See more in Biomedtracker

Latest on Minerva Neurosciences, Inc.

Pink Sheet

Better Luck Next Year: US FDA CRLs May Be Rising, But Are Not The End Of The Story

 
• By Bridget Silverman

The US Food and Drug Administration maintained a high rate of complete response letter actions for novel agent applications in 2024, but recent history suggests that many of the 16 CRL recipients will

Pink Sheet

Rare Diseases Rule, But Some Common Conditions Stand Out In Pending US Applications

 
• By Bridget Silverman

Rare diseases are almost certain to remain one of the biggest areas for novel drug development in 2024, but the orphan drug pipeline will be making space for some novel therapies for common conditions

Pink Sheet

Marching On: Eight Novel Agents Among March Goal Dates For US FDA

 
• By Bridget Silverman

The month of March will bring eight more chances for the US FDA to approve novel drugs and biologics, potentially providing a corrective to 2024’s slow start for innovative approvals. The number of us

In Vivo

Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else

 
• By Bridget Silverman

A beneficial effect of sponsorship by the largest companies in the pharma industry can be seen in the fates of novel agent applications that faced US FDA approval decisions in recent years: the applic